Form 4: Corcept Therapeutics Director Sells Shares Under 10b5-1 Plan

Corcept Therapeutics Director James N. Wilson reported the sale of Corcept Therapeutics Inc. common stock valued at over $1 million, executed under a pre-established 10b5-1 trading plan.

Summary

• Director James N. Wilson of Corcept Therapeutics Inc. (CORT) has reported transactions involving the sale of company stock.
• These sales occurred on June 16, 2026, and were conducted under a Rule 10b5-1 trading plan adopted by Mr. Wilson on March 12, 2026.
• A total of 10,000 shares were sold, generating proceeds of approximately $826,948 and $835,708 respectively, based on weighted average sale prices.
• Following these transactions, Mr. Wilson's beneficial ownership of Corcept Therapeutics common stock is detailed across direct and indirect holdings, including trusts.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by a director, despite the execution under a 10b5-1 plan.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies designed to avoid insider trading concerns.
• The reporting person, James N. Wilson, is a Director, signifying continued engagement with the company.
• The filing clearly outlines the beneficial ownership structure, providing transparency regarding holdings.

Negatives

• A significant number of shares (10,000) were sold by a Director, which could be perceived negatively by the market.
• The total value of shares sold exceeds $1.6 million, representing a notable divestment.

Risks

• Potential for negative market perception due to a Director's substantial stock sale, even if executed under a 10b5-1 plan.
• Future sales under the 10b5-1 plan could further impact share price if not balanced by positive company news.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports on past transactions.

Management Comments

• The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026, in effect at the time of this transaction.
• Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives and directors. However, the scale of the sale by a director warrants attention, especially in the context of Corcept Therapeutics' specific market performance and pipeline developments.

Stakeholder Impact

• Shareholders may view the sale by a director with caution, potentially leading to short-term price pressure.
• The company's management team and board will likely monitor market reaction to this transaction.

Next Steps

• Continued monitoring of James N. Wilson's beneficial ownership and any further transactions under the 10b5-1 plan.
• Analysis of Corcept Therapeutics' stock performance in relation to these insider sales.

Key Dates

Recommendation

While the sale by a director is a negative signal, the execution under a 10b5-1 plan mitigates concerns about non-public information. The recommendation to 'hold' reflects a neutral stance, awaiting further company-specific developments and a clearer understanding of the director's motivations beyond standard financial planning.

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transactions, Beneficial Ownership, Securities Exchange Act